Durable responses in aRCC, how do we optimise treatment?

The combination of regorafenib, nivolumab and SCRT shows promising efficacy as neoadjuvant therapy for locally advanced RC

Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients

Research highlights in lung cancer

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Antibody drug conjugates coming to primetime and new agents for breast cancer

Pancreatic, hepatic and biliary malignancies

Uncommon genetic aberrations NTRK, RET, NRG

Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant

Isa-VCd induction in NDMM patients with severe renal impairment show no new safety concerns

A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM